Fair Value Calculator Fair Value Calculator
EN DE

GIANLIFE (GIANLIFE) Fair Value & Analysis

IN · Market cap ₹51.8M

G GIANLIFE GIANLIFE · BSE
Price₹5.01
Fair Value₹7.98
Upside+59.3%
Quality38/100
Watch GIANLIFE for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹6.52 – ₹10.11

Fair value as of: Jul 5, 2026

From 14 valuation models · updated today

Share price −13.2% over the past month.

Price vs Fair Value (12 months)

₹17.26 ₹4.79 Fair Value ₹7.98 Jun 2025 Jul 2026

12‑month range ₹4.79 – ₹17.26 · fair‑value band ₹6.52 – ₹10.11 · the ₹5.01 price screens below the ₹7.98 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

GIANLIFE (GIANLIFE) currently trades at ₹5.01, while our model-based Fair Value estimate is ₹7.98 — implying the stock looks roughly 59.3% undervalued today. We read business quality at 38/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, GIANLIFE generated revenue of ₹37.6M at a net margin of -25.3%. Revenue declined 29.3% year over year. It earns a return on equity of -3.7%. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹6.52 (bear case) to ₹10.11 (bull case); at ₹5.01, the current price sits below that range. The share trades about 71% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹37.6M
Revenue growth (YoY) -29.3%
Net margin -25.3%
Return on equity -3.7%
Free cash flow ₹2.5M FY2025
Operating margin 12.2%
More key figures
EPS (TTM) ₹-0.9400
EPS growth (YoY) -70.6%

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

GIANLIFE reported revenue of ₹66.3M in FY2025 versus ₹105M in FY2021, a compound −10.8%/yr. Reported net income was −₹372K in FY2025.

Revenue −10.8%/yr
FY21 ₹105M
FY22 ₹159M
FY23 ₹119M
FY24 ₹131M
FY25 ₹66.3M
Net income
FY21 ₹20.2M
FY22 ₹43.7M
FY23 ₹10.6M
FY24 ₹41.5M
FY25 −₹372K

Is GIANLIFE fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "GIANLIFE Fair Value". https://www.fairvalue-calculator.com/stock/GIANLIFE

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is GIANLIFE (GIANLIFE) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹7.98 versus a price of ₹5.01 — about +59% (undervalued). Model-based estimate, not financial advice.
What is the fair value of GIANLIFE?
Our model-based fair value for GIANLIFE is ₹7.98 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹5.01.
What is the quality score of GIANLIFE?
GIANLIFE has a Quality Score of 38/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of GIANLIFE (GIANLIFE)?
GIANLIFE reported trailing-twelve-month revenue of about ₹37.6M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of GIANLIFE?
The net profit margin of GIANLIFE is about -25.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.